25 clinical trials found.
-
A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
The purpose of the study is to determine the safety and tolerability of NC410, and to assess the preliminary efficacy of NC410 in subjects with ...Phase
-
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
The purpose of the study is to assess the safety and tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab. XmAb®22841 is a ...Phase
-
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities
The purpose of the study is to determine the safety and tolerability of TAS0953/HM06. We want to know what is the best study drug ...Phase
-
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of the study drug CPI-0209 as monotherapy and in combination with irinotecan in ...Phase
-
A PHASE II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER
The purpose of the study is to determine the surgical safety and feasibility of atezolizumab plus tiragolumab alone (Atezo and Tira) or in combination with ...Phase
-
MasterKey-01: A Phase 1/2 Open-label Two-part Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Antitumor Activity of BDTX-189 an Inhibitor of Allosteric ErbB Mutations in Patients with Advanced Solid Malignancies
The purpose of the study is to determine the recommended phase two dose and dosing schedule of BDTX-189, as a single agent administered orally to ...Phase
-
An Open Label Phase 1 Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 with Pembrolizumab Following Radiation Therapy in the Treatment of Non-Small-Cell Lung Cancer Triple-Negative Breast Cancer or Squamous Cell Carcinoma of the Head and Neck that has Progressed on Checkpoint Inhibitors
The purpose of the study is to evaluate the safety, tolerability, and preliminary antitumor activity of TAK-676 and pembrolizumab following radiation therapy in the treatment ...Phase
-
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and tolerability of BLU-945, an orally available, highly potent and selective inhibitor of EGFR resistance ...Phase
-
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer
The purpose of the study is to evaluate niraparib plus pembrolizumab versus placebo plus pembrolizumab in participants with advanced or metastatic nonsmall cell lung cancer ...Phase
-
A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to demonstrate the improved efficacy of combining amivantamab with standard of care carboplatin-pemetrexed chemotherapy compared with carboplatin-pemetrexed chemotherapy in ...Phase
